Dmitry Balyasny’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-750,000
Closed -$51.1M 3573
2022
Q3
$51.1M Buy
+750,000
New +$41.4M 0.16% 148
2019
Q2
Sell
-315,000
Closed -$16.7M 1806
2019
Q1
$16.7M Buy
315,000
+135,000
+75% +$6.63M 0.11% 265
2018
Q4
$7.39M Buy
180,000
+142,000
+374% +$5.32M 0.05% 420
2018
Q3
$1.55M Sell
38,000
-5,000
-12% -$221K 0.01% 1063
2018
Q2
$1.94M Sell
43,000
-82,000
-66% -$3.73M 0.01% 938
2018
Q1
$6.04M Buy
+125,000
New +$6.97M 0.03% 658

Other funds holding GBT

Dmitry Balyasny's GBT Position: Q4 2022 in Review

Dmitry Balyasny sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,151,518 shares — an estimated $78.4M sold.

Dmitry Balyasny first reported a position in GBT in Q1 2016 and held it in 9 quarters. The position peaked at $78.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Dmitry Balyasny reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 1,151,518 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $78.4M.
  • Dmitry Balyasny first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 9 quarters.
  • Dmitry Balyasny's Global Blood Therapeutics, Inc. position peaked at $78.4M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.